Early access
Sign in
Taking people in United StatesPhase 3

Tests elecoglipron against placebo in adults with type 2 diabetes using insulin

Tests elecoglipron, compared with a placebo, in adults with type 2 diabetes on insulin.

Key facts

Who runs it
AstraZeneca
Where
Aurora, Brooklyn, Cary, Decatur, DeLand, Doral, Houston, Little Rock, Memphis, Morehead City, Myrtle Beach, Ocoee, Potomac, Renton, Round Rock, Sacramento, and San Antonio, United StatesSee the 17 sitesAlso in 12 other countries, 105 sites
Registry title
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin
Status
Recruiting
Phase
Phase 3
People taking part
600 people, planned
Started
8 Jul 2026
Expected to end
23 May 2028
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Elecoglipron
  • Placebo
Record updated
4 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who already take insulin and other glucose-lowering medicine. It compares elecoglipron with placebo.

Age
18 years or older
Sex
All sexes can join
Disease stage
Type 2 diabetes for at least 90 days before screening, with HbA1c from ≥ 7% (53 mmol/mol) to ≤ 10.5% (91 mmol/mol).
Earlier treatment
Stable treatment with background insulin and other glucose-lowering medicine. Stable body weight for 90 days before screening.
Biomarker or test result
HbA1c of ≥ 7% (53 mmol/mol) to ≤ 10.5% (91 mmol/mol); body mass index (BMI) of ≥ 23 kg/m2 at screening

Main reasons for not taking part

  • Type 1 diabetes, other secondary forms of diabetes, or a history of ketoacidosis or hyperosmolar coma
  • More than one episode of severe low blood sugar in the 180 days before screening, or hypoglycemia unawareness
  • History of acute or chronic pancreatitis
  • Severe heart failure (NYHA IV)
  • Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Diagnosed with T2DM for at least 90 days prior to screening
  • Stable treatment with background insulin and other background glucose-lowering medication(s)
  • HbA1c value of ≥ 7% to ≤ 10.5%
  • Body mass index (BMI) of ≥ 23 kg/m2 at screening
  • Stable body weight (self-reported or documented) for 90 days prior to screening

Who cannot take part

  • Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
  • Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
  • T1DM, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
  • Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
  • History of acute or chronic pancreatitis
  • Severe congestive heart failure (NYHA IV)
  • History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

Where in United States

Also in 12 other countries, 105 sites

  • Aurora, ColoradoHospital not named in the registryNot yet recruiting
  • Brooklyn, New YorkHospital not named in the registryNo longer taking part
  • Cary, North CarolinaHospital not named in the registryNot yet recruiting
  • Decatur, IllinoisHospital not named in the registryNot yet recruiting
  • DeLand, FloridaHospital not named in the registryNo longer taking part
  • Doral, FloridaHospital not named in the registryNot yet recruiting
  • Houston, TexasHospital not named in the registryNot yet recruiting
  • Little Rock, ArkansasHospital not named in the registryNot yet recruiting
  • Memphis, TennesseeHospital not named in the registryNot yet recruiting
  • Morehead City, North CarolinaHospital not named in the registryNot yet recruiting
  • Myrtle Beach, South CarolinaHospital not named in the registryNot yet recruiting
  • Ocoee, FloridaHospital not named in the registryTaking people
  • Potomac, MarylandHospital not named in the registryNot yet recruiting
  • Renton, WashingtonHospital not named in the registryNot yet recruiting
  • Round Rock, TexasHospital not named in the registryNot yet recruiting
  • Sacramento, CaliforniaHospital not named in the registryNot yet recruiting
  • San Antonio, TexasHospital not named in the registryNot yet recruiting

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)

The 3 groups in the trial

  • Elecoglipron dose level 1Treatment being tested

    Participants will receive elecoglipron at dose level 1 administered orally once daily.

    Treatment: Elecoglipron

  • Elecoglipron dose level 2Treatment being tested

    Participants will receive elecoglipron at dose level 2 administered orally once daily.

    Treatment: Elecoglipron

  • PlaceboPlacebo, for comparison

    Participants will receive placebo administered orally once daily.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin (Eluminate-3)
Plain-language title
Tests elecoglipron against placebo in adults with type 2 diabetes using insulinGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
4 August 2026